The Centre for Drug Development portfolioThe Centre for Drug Development portfolio
We're accelerating the delivery of the next generation of medicines to the patients who need them.
Our development portfolio contains 10 small molecules and 12 biotherapeutic agents. In addition to the agents below, we have 5 additional undisclosed programmes currently in development: a peptide, 2 small molecules and 2 antibodies.
Biologics
|
Agent (Trial) |
Target or technology |
Partnerships |
Indications |
Status |
|---|---|---|---|---|
| ALETA001 | Protein CD19, CD20 |
Aleta Biotherapeutics | Lymphoma | Phase 1 |
|
Vaccine |
Lung |
Phase 1 | ||
|
Antibody |
Rare paediatric, TYA & adult cancer |
Phase 2 |
||
| Ginisortamab (UCB6114) | Antibody Gremlin1 |
UCB | Pancreatic | Phase 2 |
| HMBD001 | Antibody HER3 |
Hummingbird Bioscience | HER3 positive solid tumours, prostate | Phase 1/2 |
| KJ103 | Antibody TROP2 |
KisoJi Biotechnology | Solid tumours | Exploratory |
|
Antibody |
Solid tumours |
Phase 1 | ||
| NVG222 | BITE ROR1, CD3 |
NovalGen | Haematological | Preclinical |
|
Antibody combination |
University of Manchester & Roche |
Rare paediatric, TYA & adult cancer |
Phase 2 | |
| UCB4594 | Antibody HLA-G1 |
UCB | Solid tumours | Phase 1 |
| VTP-600 (MAGE) | Vaccine MAGE3, NY-ESO-1 |
Barinthus Biotechnology & Ludwig Institute for Cancer Research |
Lung, oesophageal | Phase 1/2 |
Small molecules
|
Agent (Trial) |
Target |
Partnerships |
Indications |
Status |
|---|---|---|---|---|
|
TLK, ALK |
Rare paediatric, TYA & adult cancers | Phase 2 | ||
| BT1718 | MT1-MMP | Bicycle Therapeutics | Solid tumours, lung | Phase 1/2 |
|
TLK, ALK, ROS1 |
Rare paediatric, TYA & adult cancers | Phase 2 | ||
| HTL0039732 | EP4 | Nxera | Solid tumours | Phase 1/2 |
|
Cdc7 |
Solid tumours, lung, colorectal, ovarian |
Phase 1/2 | ||
| TT702 (CURATE) |
adenosine, |
Solid tumours |
Phase 1/2 |
|
|
BRAF, MAP, MEK |
Rare adult cancers | Phase 2 |
News, features and updates
Discover the latest news and press releases related to Centre for Drug Development partnering, clinical trials, patient involvement activity and more.
Partnering with us
We partner with academics, pharmaceutical, and biotech companies worldwide to develop novel cancer treatments.
Our DETERMINE trial
DETERMINE is the first UK national precision medicine trial in rare cancers, testing a range of therapies targeting key genetic changes in cancer cells.